Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of cana...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Diabetol Metab Syndr
Auteurs principaux: Yagi, Shusuke, Hirata, Yukina, Ise, Takayuki, Kusunose, Kenya, Yamada, Hirotsugu, Fukuda, Daiju, Salim, Hotimah Masdan, Maimaituxun, Gulinu, Nishio, Susumu, Takagawa, Yuriko, Hama, Saori, Matsuura, Tomomi, Yamaguchi, Koji, Tobiume, Takeshi, Soeki, Takeshi, Wakatsuki, Tetsuzo, Aihara, Ken-ichi, Akaike, Masashi, Shimabukuro, Michio, Sata, Masataka
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2017
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628447/
https://ncbi.nlm.nih.gov/pubmed/29034006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-017-0275-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires